Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Other Events

ME Staff 8-k
-
0

Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Other Events
Item 8.01. Other Events.

On January29, 2018, Onconova Therapeutics,Inc. (the “Company”) updated its corporate presentation (the “Presentation”), which is attached hereto as Exhibit99.1 hereto and incorporated herein by reference.

Forward Looking Statements

This report contains forward-looking statements about the Company based on management’s current expectations which are subject to known and unknown uncertainties and risks. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. The Presentation assumes the Company raises capital for disclosed product development plans. The Company’s actual results could differ materially from those discussed due to a number of factors, including, but not limited to, the Company’s ability to raise additional financing on favorable terms, the success of the Company’s clinical trials and the Company’s ability to obtain regulatory approvals and other risk factors outlined in the Company’s annual and quarterly reports filed with the Securities and Exchange Commission. The Company is providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements, whether written or oral, that may be made from time to time, as a result of new information, future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Exhibit

99.1

Corporate Presentation dated January29, 2018


Onconova Therapeutics, Inc. Exhibit
EX-99.1 2 a18-3985_1ex99d1.htm EX-99.1 Exhibit 99.1 Corporate Update January 29,…
To view the full exhibit click here

About Onconova Therapeutics,Inc. (NASDAQ:ONTX)

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.